Based on the above viewpoints, while the risk classification by the expression of TPX2 has been accomplished, treatment including ICI combined with other classical therapies may be applied to the advanced RCC, that is, TPX2 could provide guidance for the clinical use. This evidence concerns the gene TPX2 and renal cell carcinoma.